Mineralocorticoids have been implicated in the pathogenesis of
diastolic heart failure. On the contrary,
angiotensin (Ang)-(1-7) has emerged as a potential strategy for treatment of cardiac dysfunction induced by excessive
mineralocorticoid receptor activation. A critical question about the cardioprotective effect of Ang-(1-7) in hypertensive models is its dependence on blood pressure (BP) reduction. Here, we addressed this question by investigating the mechanisms involved in Ang-(1-7) cardioprotection against
mineralocorticoid receptor activation. Sprague-Dawley (SD) and transgenic (TG) rats that overexpress an Ang-(1-7) producing fusion
protein (TG(A1-7)3292) were treated with
deoxycorticosterone acetate (
DOCA) for 6 weeks.
After treatment, SD rats became hypertensive and developed ventricular
hypertrophy. These parameters were attenuated in TG-
DOCA. SD-
DOCA rats developed diastolic dysfunction which was associated at the cellular level with reduced Ca(2+) transient. Oppositely, TG-
DOCA myocytes presented enhanced Ca(2+) transient. Moreover, higher
extracellular signal-regulated kinase phosphorylation, type 1
phosphatase, and
protein kinase Cα levels were found in SD-
DOCA cells. In vivo, pressor effects of
DOCA can contribute to the diastolic dysfunction, raising the question of whether protection in TG was a consequence of reduced BP. To address this issue, BP in SD-
DOCA was kept at TG-
DOCA level by giving
hydralazine or by reducing the
DOCA amount given to rats (Low-
DOCA). Under similar BP, diastolic dysfunction and molecular changes were still evident in
DOCA-
hydralazine and SD-low-
DOCA, but not in TG-
DOCA. In conclusion, Ang-(1-7) protective signaling against
DOCA-induced diastolic dysfunction occurs independently of BP attenuation and is mediated by the activation of pathways involved in Ca(2+) handling,
hypertrophy, and survival.